

Statement of Advice:

**canakinumab (Ilaris[®]) 150 mg/ml, powder for solution for injection
intended (No: 658/10)**

Novartis Pharmaceuticals

08 October 2010

ADVICE: in the absence of a submission from the holder of the marketing authorisation

canakinumab (Ilaris[®]) 150 mg/ml, powder for solution for injection is not recommended for use within NHSScotland.

Indication under review: Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents and children aged 4 years and older with body weight above 15 kg.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result SMC cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Chairman,
Scottish Medicines Consortium**